October 20, 2009

                       

 

A new Pfizer Animal Health was unveiled last week as Pfizer's acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed.

 

Pfizer Animal Health is now the world's leader in the discovery, development, manufacture and sales of veterinary vaccines and medicines for livestock and companion animals.

 

The acquisition of many of Fort Dodge's US products allows Pfizer Animal Health to greatly diversify its US portfolio, as well as broaden its offering in all animal health segments. Pfizer Animal Health now offers an enhanced portfolio in beef, dairy, and companion animals, as well as a redefined product line for swine, equine and poultry.

 

"The products, services and expertise we are gaining strengthen what is already a robust US portfolio and will enhance our leading position in the animal health marketplace," said Clint Lewis, president of US Operations for Pfizer Animal Health.

 

Pfizer Animal Health also announced that all current US pricing, product distribution, programs and policies for Pfizer Animal Health products, including the acquired Fort Dodge products, will remain in place through 2009.

 

Here is a summary of Pfizer Animal Health's new US product portfolio:

   

As the leader for beef and dairy animal health solutions, Pfizer will further enhance its position with the addition of FACTREL (gonadorelin hydrochloride) and the pioneer line of SYNOVEX implants. These products complement the current US cattle portfolio that includes DRAXXIN (tulathromycin), DECTOMAX, EXCEDE (ceftiofur crystalline free acid), EXCENEL (ceftiofur hydrochloride), BOVI-SHIELD GOLD, LUTALYSE (dinoprost tromethamine), ORBESEAL, and SPECTRAMAST (ceftiofur hydrochloride).

 

Pfizer Animal Genetics also continues to explore opportunities to apply genomics technology to livestock health and management solutions.

 

For the swine market, Pfizer Animal Health will offer a comprehensive range of solutions and services to strengthen its offering with the full line of SUVAXYN brands, including SUVAXYN PCV-2 vaccine for circovirus. This addition rounds out an already broad product line that includes RESPISURE, FLUSURE, DRAXXIN, and EXCEDE.

 

Pfizer Poultry Health will strengthen its position in the poultry industry with the addition of a broad range of poultry vaccines including POULVAC and MATERNAVAC IBD-Reo, a leading broiler-breeder vaccine.

 

Equine

 

Joining an already industry-leading equine franchise that includes established brands such as STRONGID (pyrantel pamoate), DORMOSEDAN (detomidine hydrochloride), and HYLARTIN (sodium hyaluronate) are Fort Dodge's WEST NILE INNOVATOR, FLU VAC INNOVATOR and QUEST(moxidectin) and QUEST PLUS (moxidectin/praziquantel).

 

Companion Animals

 

The vaccine LYMEVAX complements the current VANGUARD canine vaccine line, and several anesthetic products help round out the small animal portfolio. They join current innovative offerings that include REVOLUTION (selamectin), CERENIA (maropitant citrate), CONVENIA (cefovecin sodium), RIMADYL (carprofen) and SLENTROL (dirlotapide).

 

Pfizer Animal Health, a business of Pfizer Inc., is a world leader in discovering and developing innovative animal prescription medicines and vaccines, investing an estimated US$300 million annually.